GHRP-6 vs Ipamorelin: Selectivity, Appetite Effects and Human Evidence
A structured comparison of GHRP-6 and ipamorelin covering receptor pharmacology, appetite observations and human evidence gaps.
Executive Summary
GHRP-6 and ipamorelin are both growth-hormone secretagogues acting through the ghrelin receptor. That shared target does not make their pharmacology, effects, human datasets or safety profiles identical.
What Selectivity Claims Mean
Ipamorelin is often described as more selective in early pharmacology discussions. Selectivity is a receptor-level concept; it does not by itself prove better long-term tolerability or superior clinical outcomes. Those claims require adequately powered comparative human trials.
Appetite-Related Observations
Ghrelin signaling participates in hunger and energy regulation, and appetite effects are often discussed for GHRP-6. Controlled findings must be separated from preclinical data and anecdotes. Appetite is neither proof of therapeutic benefit nor a reliable proxy for GH efficacy.
Limits of Human Evidence
Small studies can characterize acute hormone release and short-term physiology. They are poorly suited to detect rare harms or establish durable changes in body composition, recovery, function or disease outcomes. Direct head-to-head evidence is necessary before claiming one is safer or more effective.
Regulatory and Sport Context
Neither compound has an FDA-approved indication. Athletes should consult the current WADA Prohibited List and applicable testing rules rather than seller descriptions.
Key Insight
GHRP-6 and ipamorelin share a receptor family but differ in reported pharmacology. Available evidence does not support simple rankings for muscle gain, fat loss, recovery or safety.